Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Leukemia. 2016 Feb 3;30(7):1606–1609. doi: 10.1038/leu.2016.6

Figure 1.

Figure 1

Differential prognostic impact of ACAs in myeloid vs lymphoid blast phase of CML. (a). Prognostic impact of ACAs in CML, BP (all cases). (b, c) Prognostic impact of ACAs in CML, MyBP (b) and LyBP (c). (d, e) Prognostic impact of the complexity of ACAs in CML, MyBP (d) and LyBP (e). (f) Prognostic impact of single high-risk ACAs vs other single ACAs in CML, MyBP. High-risk ACAs include 3q26.2 rearrangement, i(17q) and − 7/7q del. (g) Prognostic impact of the emerging time of ACAs in CML, MyBP. (h, i) Prognostic impact of ACAs in CML, MyBP, without (h) and with (i) allo-HSCT. Overall survival was calculated from the date of diagnosis of BP to the date of last follow-up or death. A total of 11 patients including 10 with MyBP and one with LyBP were followed-up in outside institutions and their status of transplantation was unknown. Survival curves were built using the Kaplan–Meier method and differences in survival were evaluated by the log-rank test. The study is approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center.